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Objectives:  To determine the prevalence of benign prostatic hyperplasia (BPH) and correlates International
Prostate Symptom Score (IPSS), peak/maximum flow rate (Qmax), quality of life (QoL) score and prostate
volume (PV) amongst male adults in a rural setting in Nigeria.
Subjects  and  methods:  This is a community-based cross-sectional survey conducted amongst 615 men.
Subjects selected using multi-staged sampling technique were interviewed for presence of lower urinary tract
symptoms (LUTS) in their houses. Severity of symptoms was assessed using International Prostate Symptom
gital rectal examination (DRE), uroflowmetry and prostate scan were carried
entres. Criteria for diagnosis of BPH were prostatic volume ≥  30 cm3 with
r Qmax < 15 mL. Relationships between variables were determined using
her’s exact tests.Score (IPSS) questionnaire. Di
out in nearby primary health c
moderate/severe LUTS and/o
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Results:  The overall prevalence of LUTS was 57.4% while 28.5% had moderate-to-severe IPSS with average
score of 12.3 ±  5.2. More than half (56.1%) reported impaired QoL with average score of 3.4 ±  1.3. The
DRE and ultrasound prevalences of enlarged prostate were 68.3% and 64.9% respectively. About 29% had
abnormal Qmax. Both QoL and Qmax had significant relationship with IPSS (p  < 0.001) while none exists
between prostate size and IPSS (p  = 0.339). The overall prevalence of BPH was 237 per 1000 men (23.7%).
The age-specific prevalence rates increased from 104 per 1000 men in the fifth decade to 429 per 1000 in
men >90 years.
Conclusion:  The burden of clinical BPH is very high amongst Nigerian men and the prevalence increases
with age. There is need for more public awareness because of the significant impairment in the QoL
associated with BPH symptoms.
















































































enign prostatic hyperplasia (BPH) is the most common neoplasm
nd a significant cause of urinary symptoms in the adult males [1].
nlargement of the prostate occurs with age leading to bladder out-
et obstruction, which manifests with symptoms of impaired urine
oiding and/or storage referred to as lower urinary tract symptoms
LUTS). Although BPH is not life threatening, its clinical manifes-
ation as LUTS reduces the patient’s quality of life (QoL) [2].
he prevalence of BPH varies and depends on the criteria as well
s research settings. Many individuals with histological BPH are
symptomatic making clinical BPH the appropriate terminology
hen conducting research on BPH in the community [3]. Sev-
ral community-based epidemiological studies have documented
he prevalence of BPH ranging from 30 to 50% and 18.1 to 25.3%
n hospital-based and community-based settings, respectively [4–6].
owever, such studies are relatively scarce in sub-Saharan Africans
here almost all the existing reports are hospital-based settings.
econdly, there are differences in the reported prevalence of LUTS
nd BPH among countries, possibly arising from cultural or lin-
uistic differences. Because this finding suggests that the results
n one country might not be applicable to others, it is necessary
o investigate the natural history of LUTS in each one [5]. As the
opulation of ageing men increases, BPH has become an important
opic of public health concern. The only community-based study in
igeria utilized the International Prostate Symptom Score (IPSS)
s the only tool to determine the prevalence of BPH [7]. Another
tudy conducted amongst Ghanaian men utilized IPSS and prostatic
nlargement by digital rectal examination (DRE) [8]. The data in
hese studies were not collected using standardized tools and clini-
al definitions; therefore the diagnostic and epidemiological values
f these studies are limited. Therefore, the aim of this study was
o determine the prevalence of BPH using standardized criteria of
PSS, peak/maximum flow rate (Qmax) and ultrasound measured
rostate volume (PV) amongst community-dwelling men in a rural
etting. It also aimed at establishing statistical associations between
hese variables and analyzed changes with age.
ubjects  and  methodshis was a population-based descriptive cross-sectional survey
esigned to assess the prevalence of clinical BPH amongst




rea (L.G.A.) of Ekiti state, Southwest, Nigeria. Approval for the
tudy was obtained from the research and ethics committee of Lagos
niversity Teaching Hospital, Lagos. Additional approvals were
btained from authority of the L.G.A. as well as the traditional chiefs
f the towns selected for the study. The study population comprises
f all male adults above the age of 40 years who provided written
onsent to participate. A multi-stage sampling technique was used.
irst, three of the eleven electoral wards were selected followed
y selection of a town in each ward by simple random sampling.
bout 25–40 streets were selected in each town also by simple ran-
om sampling while about 3–8 houses were selected in each street
y systematic sampling technique. Where more than one man lives
n any selected house, one of them is selected by simple balloting.
ll selected men were interviewed in their houses for LUTS using
 semi-structured questionnaire including the IPSS questionnaire.
ubjects were then mobilized to nearby primary healthcare centre
n each town where they had a DRE carried out by two urologists
o document the presence of enlarged prostate. Physical examina-
ion was followed by prostate scan to determine the prostate volume
erformed by a radiologist using a portable SONOSCAPE A5 ultra-
ound machine with a 3.5 MHz abdominal probe. They all had
roflowmetry using UROCAP III (Laborie, Canada) uroflowme-
er. Data collection took place on three consecutive weekends in the
elected three communities. Data were analyzed with SPSS ver-
ion 18. The diagnostic criteria for clinical BPH were prostatic
olume of ≥30 mL with moderate/severe IPSS (IPSS ≥  8) and/or
max <15 mL/s; without symptoms, physical signs and radiologic
ndings suggestive of prostate cancer. Subjects already on treat-
ent for BPH were included irrespective of their symptom severity.
earson’s chi-squared and Fisher’s exact tests were used to establish
elationships between variables with level of significance (p) set at
.05.
esults
 total of 658 adult males were recruited but 615 completed the
tudy. Ages of the participants ranged from 41 to 93 years with a
ean of 64.3 ±  12.6 years (Table 1).
hree hundred and fifty-three men (57.4%) had at least one LUTS
hile 256 (41.6%) were asymptomatic. Two hundred and ninety-hree (47.6%) had at least one irritative symptom while 238 (38.7%)
ad at least one obstructive symptom. Of all the participants, 175
28.5%) were highly symptomatic consisting of 172 (48.7%) with
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Table  1  Age distribution of the participants.







Table  3  Distribution of prostate volume versus age groups.
Age (years) PV (mL)
<30 mL ≥30 mL Total p-value
n (%) n (%) n (%)
41–50 86 (74.8) 29 (25.2) 115 (100.0) <0.001
51–60 61 (39.9) 92 (60.1) 153 (100.0)
61–70 42 (25.5) 123 (74.5) 165 (100.0)
71–80 23 (20.5) 89 (79.5) 112 (100.0)
81–90 4 (8.2) 45 (91.8) 49 (100.0)
>90 0 (0.0) 21 (100.0) 21 (100.0)
Total 216 (35.1) 399 (64.9) 615 (100.0)
Table  4  Distribution of Qmax amongst the participants.
Status Qmax (mL/s) Frequency (n) Per cent (%)
Abnormal
(0–14)
























moderate/severe symptoms (IPSS ≥  8) and 3 on indwelling catheter
for acute urinary retention. Average symptom score was 12.3 ±  5.2.
A statistically significant relationship was found between age and
IPSS (Table 2). Twenty-two of the participants were already on
medication(s) for BPH.
Four hundred and twenty (68.3%) had abnormally enlarged prostate
while 195 (31.7%) had no prostate enlargement by DRE estima-
tion. Five participants had hard, nodular and craggy prostates with
obliterated median groove and/or fixed rectal mucosa suggestive of
malignancy.
Table 3 shows the prevalence of prostatic enlargement defined as
prostate volume ≥  30 mL using trans-abdominal ultrasound esti-
mation. There was a statistically significant association between
increasing age and prostate volume (p  < 0.001). Of the 399 with
ultrasound finding of enlarged prostates, only 279 (69.9%) had at
least one symptom constituting 79% of the symptomatic men. One
hundred and twenty asymptomatic men had enlarged prostates.
Overall, 179 of the participants (29.1%) had abnormal Qmax with
the cut off mark of 15 mL/s set for the study. All these men were
symptomatic while the remaining 174 symptomatic participants had
Qmax ≥15 mL/s (Table 4).
The QoL was significantly impaired among men with IPSS ≥  8
(average score = 3.4 ±  1.3). The relationship between QoL score,
PV, Qmax and IPSS amongst the symptomatic men is depicted
in Table 5. Both QoL score and Qmax had significant relation-
ship with IPSS (p  < 0.001). There is also a positive relationship
between prostate enlargement and presence or absence of symptoms
(p  < 0.001). However, further analysis of the PV and IPSS yielded
no statistically significant association (p  = 0.339).
Of the 615 men, 126 (20.5%) did not meet any of the criteria for the




Table  2  Distribution of IPSS versus age range of participants.
Age group No symptom Mild IPSS (1–7) Moderate IPSS (8–18)
41–50 94 (81.7) 17 (14.8) 4 (3.5) 
51–60 90 (58.8) 35 (22.9) 22 (14.4) 
61–70 53 (32.1) 66 (40.0) 33 (20.0) 
71–80 19 (17.0) 39 (34.8) 40 (35.7) 
81–90 6 (12.2) 21 (42.9) 14 (28.6) 
>90 0 (0.0) 0 (0.0) 13 (61.9) 
Total 262 (42.6) 178 (28.9) 126 (20.5) 
p < 0.001.nd fifty (24.4%) had combination of at least two criteria while 114
18.5%) had combination of the three (Fig. 1). Based on the criteria
or diagnosis of BPH, 143 men met these criteria in this study.
owever, five men with clinical features suggestive of malignancy
ere excluded. Eight of the 22 men on medication for BPH had
ild IPSS and normal Qmax while 14 of them still met the criteria.
ith the inclusion of these eight men i.e. (143 −  5 + 8 = 146), the
ercentage of men with clinical BPH was 23.7% with an estimated
revalence of 237 per 1000 adult men.
he prevalence of BPH was 104 per 1000 men in the fifth decade
f life and increased to the highest prevalence of 429 per 1000 men
n the ninth decade (Fig. 2). There was a significant association
etween the prevalence and increasing age (p  < 0.030).
 Severe IPSS (19–35) On indwelling catheter Total (n/%)
0 (0.0) 0 (0.0) 115 (18.7)
6 (3.9) 0 (0.0) 153 (24.9)
12 (7.3) 1 (0.6) 165 (26.8)
12 (10.7) 2 (1.8) 112 (18.2)
8 (16.3) 0 (0.0) 49 (8.0)
8 (38.1) 0 (0.0) 21 (3.4)
46 (7.5) 3 (0.5) 615 (100)
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Table  5  Association between QoL score, PV, Qmax and IPSS.
Variable Severity of symptoms p-value
No symptom Mild (0–7) Moderate (8–19) Severe (20–35) Total
Quality of life score Good (0–2) 262 (100.0) 113 (63.5) 34 (27.0) 8 (16.3) 417 (67.8) <0.001*
Fair (3–4) 0.0 (0.0) 65 (36.5) 53 (42.0) 10 (20.4) 128 (20.8)
Poor (5–6) 0.0 (0.0) 0.0 (0.0) 39 (31.0) 31 (63.3) 70 (11.4)
262 (42.6) 178 (28.9) 126 (20.5) 49 (8.0) 615 (100.0)
Prostate size Normal 126 (26.7) 143 (64.0) 4 (13.5) 3 (30.6) 216 (35.1) <0.001**
Enlarged 136 (73.3) 35 (36.0) 122 (86.5) 46 (69.4) 399 (64.9)
262 (42.6) 178 (28.9) 126 (20.5) 49 (8.0) 615 (100.0)
Qmax Normal 262 (100.0) 136 (76.4) 34 (27.0) 4 (8.2) 436 (70.9) <0.001*
Abnormal 0.0 (0.0) 42 (23.6) 92 (73.0) 45 (91.8) 179 (29.1)
262 (42.6) 178 (28.9) 126 (20.5) 49 (8.0) 615 (100.0)
* Fisher’s exact test.
** Pearson’s chi-squared test.
Figure  1  Diagnosis of clinical BPH using different diagnostic
criteria.







































enign prostatic hyperplasia is the most common benign neoplasms
n elderly men worldwide [1]. It is a significant health care problem
ue to its high prevalence and the cost associated with its treatment.
iven the ageing of populations worldwide, the cost burden asso-
iated with the treatment of LUTS suggestive of BPH will increase
ubstantially over the next few decades [9]. This present study is
he first in Nigeria to determine the prevalence of BPH using other
iagnostic criteria other than IPSS.
he prevalence of LUTS in middle-aged and elderly men has been
ocumented to be high, ranging from 11 to 65% in many studies
4–6]. In our study, the overall prevalence of LUTS was 57.4%,
hich is similar to the prevalence reported in other studies [4,5].
ike other studies, the storage or irritative symptoms were more
revalent among the participants than obstructive or voiding symp-
oms [4–6]. A major criterion in the diagnosis of BPH is symptom
everity assessed by the IPSS. Using this pre-defined cut-off score,
8.5% of all participants experienced moderate/severe symptoms
egarded as significant LUTS corresponding to IPSS of ≥8. This
ncludes the three men on indwelling urethral catheter at the time of
he study. Though the prevalence of moderate/severe symptom was
igher than documented in some studies which range between 16.6
nd 24.4%, it however agrees with them in term of increasing preva-
ence with age [5]. When the association between age and IPSS was
xamined, there was a tendency for moderate/severe LUTS with
ncreasing age.
linical BPH may not be life threatening; however, its manifestation
s LUTS interferes with QoL [2]. More than half (56.1%) of the
ymptomatic men in this study reported impairment in their QoL due
o symptoms of BPH while about one-fifth, 19.8%, had poor QoL.
ike reported in other studies, the severity of BPH-related symptoms
as significantly related to QoL. In fact, about 89.5% of those who
ad moderate/severe symptoms formed the population of the one-
fth with poor QoL while all men with severe symptoms and those
n catheter had poor QoL scores. The severity of symptoms was
ignificantly associated with QoL score. The higher the IPSS, the

























































Prevalence of BPH amongst Nigerian men 
I-PSS had no significant association with the prostate size. In fact,
almost two-thirds of 399 men with radiological evidence of enlarged
prostates had no or mild symptoms and normal Qmax values. These
findings are in conformity with earlier reports [10,11].
The prevalence of prostate enlargement by DRE in this study was
68.3%. This is higher than 62.3% reported in a study conducted
by Chokkalingam et al. [8] amongst Ghanaians. This may not be
unconnected with the subjective error and inter-observer variabil-
ity inherent in DRE. To minimize this, two urologists performed
the DRE in our study. The prevalence of prostatic enlargement by
trans-abdominal ultrasound was 64.9%. There was a great corre-
lation between the DRE and ultrasound estimation of the prostatic
size, however DRE seems to overestimate the prostate size as some
men with DRE findings of enlarged prostate eventually had a normal
prostatic volume of <30 mL with ultrasound estimation. This sug-
gests that DRE provides a crude estimate of the prostatic size and a
more accurate method is required for accurate determination of the
PV [12]. The prevalence of prostatic enlargement increased with age
in conformity with earlier reports [3,5]. Using the ultrasound find-
ings, the prevalence of enlarged prostate increased steadily from
25.2% in the fifth decade to 91.8% ninth decade of life respec-
tively. All the participants beyond ninth decade of life had enlarged
prostates. There was a statistically significant increase in the pro-
portion of men with a volume of ≥30 mL with increasing number
of decades of life (p  < 0.001). These findings conform to the natural
history of benign prostatic enlargement (BPE) documented in other
continents other than African communities [13–16].
The only way to determine objectively whether men are urodynami-
cally obstructed is by performing detrusor pressure-uroflow studies,
which unfortunately are too invasive for use in large population
studies. Therefore, the determination of Qmax is generally used
as screening test when bladder outflow obstruction is suspected.
Like LUTS, other problems other than BPH can cause abnormal
flow rate and this should be borne in mind when interpreting results
of uroflowmetry. In this study, more than two thirds (70.9%) of
all participants had a satisfactory Qmax of ≥15 mL/s while 28.1%
had abnormally low Qmax (<15 mL/s). The percentage of men with
abnormal Qmax increased significantly to 50.4% amongst the symp-
tomatic men. The Qmax was found to correlate well with symptom
severity and QoL scores (p  < 0.001) but not with PV. Age factor,
which has reciprocal or inverse relationship with Qmax and IPSS
but direct relationship with prostatic size, may be the reasonable
explanation for this finding. This is consistent with the findings of
other researchers [17,18].
It is important to note that BPE is not synonymous with BPH as
almost all men above middle age will have some degrees of pros-
tatic enlargement [19]. However, not all of these men will have
symptoms. In our study, only a third (32.6%) of men with enlarged
prostate had moderate to severe symptoms. An additional fifth of this
group of men had mild symptoms while the rest were purely asymp-
tomatic. Even though men with enlarged prostate are more likely to
have LUTS, the severity of their symptoms does not correlate with
their prostate size. Several other studies have reported this [19,20].
In fact, about 18% of all the men who had enlarged prostates were
completely asymptomatic. This has shown that BPE- a concept that
emanated from this observation in earlier studies is clearly different
from clinical BPH. In addition, five participants who reported mild
symptom severity were found to have abnormally low Qmax. This






PSS, which may be affected by method of questionnaire adminis-
ration, culture, language and other factors [21–23]. This suggests
hat it may be better to incorporate uroflowmetry findings in the
riteria for the diagnosis of BPH to avoid under- or over-estimation.
roflowmetry is a relatively objective and simple way of demon-
trating lower urinary tract obstruction. Altogether, ninety (14.6%)
ubjects had either moderate/severe LUTS or abnormal Qmax or
oth, but no prostatic enlargement. This observation points to the
act that BPH is not the only cause of LUTS in ageing men. These
en require further investigations to rule out other possible causes
f LUTS like urethral stricture disease, prostate cancer, urinary tract
nfection, neuropathic bladder and urolithiasis. This is also not sur-
rising because women who do not have prostate have LUTS from
on-prostatic causes [24].
enerally, the three criteria for diagnosing BPH overlap to varying
egrees in different patients. The diagnosis of clinical BPH includes
aking a medical history of the patient and recording the IPSS, DRE,
max and ultrasound results, but it is difficult to define BPH from
hese tests. Furthermore, it is impossible to choose any measure that
s superior to the others in terms of efficacy [20]. Hence, researchers
ave reported data on the prevalence of BPH according to their own
efinitions. The prevalence of clinical BPH vary from a relatively
ow prevalence of 10.3% to a high prevalence of 43% depending
n the criteria utilized, country and age range of the study [6,25].
espite the abundance of information, prevalence of BPH using
tandard criteria has not been documented in Nigerian and Sub-
aharan African populations. Using the criteria, which took into
onsideration the acceptable values of these parameters, BPH is
efined by finding of an enlarged prostate ≥30 mL with moderate-
o-severe LUTS (I-PSS > 8) and/or decreased Qmax of <15 mL/s
5,26,27]. Of the 615 participants, only 146 were diagnosed to have
linical BPH based on the criteria stipulated above. From these data,
he estimated prevalence of clinical BPH in this study was 23.7%
r 237 per 1000 men. This is higher than the prevalence of 11.7%
ocumented in a study amongst Spanish men [26] and 10.3% in
nother study in Netherlands [25]. It is also slightly higher than the
eported prevalence 21.0% in Jeju Island, South Korea [5] and of
9.7% in Korea [28]. However, it is very similar to the prevalence
f 23.5% in Pingliang, China [4]. These studies utilized the same
riteria with ours [4,5,28]. On the other hand, the prevalence in
ur study is lower than the prevalence of 25.3% reported amongst
cottish men possibly due to use of 20 mL as the cut-off volume for
rostatic enlargement in their own study [6]. The difference in the
revalence rates may also be attributable to differences in the study
esigns regarding sample selection and diagnostic criteria used for
ase definition to estimate disease prevalence. The prevalence rate
n this study, though higher, was not significantly different from
ates in the other countries using the same criteria and age range
4,5].
enign prostatic hyperplasia is a disease of ageing men. There
s hardly any study that reported contrary opinion on the positive
ssociation between age and occurrence of BPH. In our study, the
ge-specific prevalence rates increased from 104 per 1000 men in
he fifth decade of life to 429 per 1000 men above ninety years. The
ncrease was linear from the fifth to the seventh decade before it
lateaus and increased in the eight decade of life again. This concurs
ith the findings in different parts of the world [25,29]. Although
he absolute prevalence differs widely among studies, suggesting
ome possible cultural differences in reporting urinary symp-



















































arallel the age-related increase in prostate volume in autopsy stud-
es [29].
onclusions
he burden of LUTS and BPH amongst Nigerian men is very high
nd irritative symptoms were more prevalent than obstructive symp-
oms. The overall prevalence of BPH in this study was 23.7% or
37 per 1000 men and the age-adjusted prevalence increases with
ncreasing age. Very few of the men diagnosed in this study were on
edication for BPH suggesting the need for more public awareness
bout this benign disease with manifestations that can affect QoL
dversely.
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